![5000100-flag[1].jpg](https://cdn.european-virus-archive.com/cdn/farfuture/BIcd6Z7a1Uzb5LahErSGdoyqhDpItm5zvumsM9sBY60/mtime:1484756601/sites/default/files/5000100-flag%5B1%5D.jpg)
The best way to get viral material within the Scientific Community. Browse our viruses and derived products from the EVAg Portal.
A unique biological resource in the field of virology, readily available online. Users may benefit from special funding to access to products of interest, do not hesitate to apply.
An international group of 25 laboratories, including 16 EU member state institutions and 9 non-EU institutions, that represent an extensive range of virological disciplines.
An open entity aiming at developing synergies and complementary capabilities in such a way as to offer an improved access to researchers.
The quality of viruses and derived products is a key consideration when our products are to be made available. Improvements on quality process will be addressed during the project.
EVAg generates and distributes globally diagnostic materials and protocols in the event of epidemiological emergencies.
Focused on the creation of new tools, techniques and concepts to develop the infrastructure and to provide easier and less expensive access to virological materials.
A user-friendly web Portal with a continuously increasing number of viruses and derived products. Start here...
The EVAg initiative will increase competitiveness and, provides for a strong interaction with industry and a promising foundation for the innovation process between academia and industry.
- The European Commission -
The initiative has an important social impact with particular emphasis on human disease.
- The European Commission -
The quality of the installations cooperating in this consortium is excellent, representing some of the best available infrastructures across the EU and world-wide.
- The European Commission -
Our EVAg partner at Bernard Nocht Institute just published this paper on a new ELISA assay for #Lassafever virus detection. BNI is giving access to its large collection of Lassa virus strains via the EVAg online portal https://t.co/y8T9lPE2c2
@ISARICAR Could we get information on the possibilities to have an exhibition stand at your next conference please ?
Interested in Proficiency tests for #rabies #virus ? Our partner @APHAgovuk offers a panel of 8 samples, custom made to meet your geographical/host species needs. Free of charge access available, enquiry on our website https://t.co/KsYZvDcKFt https://t.co/2fVvdOfl4K
Our partner Xavier de Lamballerie's lab (Marseille) has just added a 3-days onsite training offer on the EVAg online portal: how to lyophilize viral strains and derived material for convenient preservation. Free of charge training possible, request online: https://t.co/G1morFQoZf https://t.co/aAZRXm2Txz
Shaping the future of #goarn #gmp2017 https://t.co/4nBAgHktCk
Working on strengthening regional capacities and network #goarn #gmp2017 https://t.co/kIi0YfckE0
A one-day workshop was organised by our EVAg partner Animal and Plant Health Agency, APHA on the 15th of October, 2016. The aim of this workshop was t... read more
The next American Society of Tropical Medicine and Hygiene Annual Meeting will be held in November 13-17, 2016, in Atlanta, Georgia, USA.... read more
The World Health Organisation (WHO) has warned that Zika virus (ZIKV), a mosquito-borne virus that can infect humans, is likely to spread across the ... read more
We at Luminex were sincerely appreciative of your willingness to work with us during the development of our xMAP® MultiFLEX™ Zika RNA Assay. The materials from EVAg supported our FDA submission, which is now authorized for emergency use.
Sarah M. Dunlap, PhDDirector, Clinical Operations - Luminex Corporation
We received high quality products at no cost. It helped us a lot in achieving our project. Thank you!
John UserR & D - Laboratory
